72700-23-3

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
4-Chloro-6,7-methylenedioxyquinazoline is utilized as a compound of interest in pharmaceutical research and drug development due to its quinazoline structure, which has been associated with a range of biological activities. These activities include anticancer, antimalarial, and antimicrobial properties, making it a candidate for further investigation and research in the field of drug discovery and medicinal chemistry.

Upstream product

• 94-53-1 Piperonylic acid 
• 40680-63-5 methyl 6-aminobenzo[d][1,3]dioxole-5-carboxylate 
• 326-56-7 methyl 3,4-methylenedioxybenzoate 
• 721-00-6 methyl 6-nitrobenzo[d][1,3]dioxole-5-carboxylate 
• 593-71-5 Chloroiodomethane 
• 1145671-36-8 4-chloro-6,7-dihydroxyquinazoline 
• 269-53-4 [1,3]dioxolo[4,5-g]quinazoline 
• 165330-00-7 ethyl (1,3-benzodioxolan-5-yl)carbamate 
• 14268-66-7 benzo[1,3]dioxolo-5-ylamine 
• 28310-11-4 6,7-methylenedioxyquinazoline-4(3H)-one 

Downstream Products

• 1256394-35-0 4-(N-methyl-3-chloro-4-fluoroanilino)-6,7-methylenedioxyquinazoline 
• 1256394-36-1 4-(N-methyl-4-bromo-2-fluoroanilino)-6,7-methylenedioxyquinazoline 
• 1456819-60-5 ([1,3]dioxolo[4,5-g]quinazolin-8-yl)-(3'-methansulfonamidopheyl)amine hydrochloride 
• 1401243-68-2 ([1,3]dioxolo[4,5-g]quinazolin-8-yl)-(biphenyl-3'-yl)amine hydrochloride 
• 1355620-31-3 5-(5-{2H-[1,3]dioxolo[4,5-g]quinazolin-8-yloxy}pyridin-2-yl)-2-[(4-fluorophenyl)amino]-3-methyl-3-pyrimidin-4-one 
• 1348516-27-7 ([1,3]dioxolo[4,5-g]quinazolin-8-yl)-(3'-bromophenyl)amine hydrochloride 
• 1348211-74-4 ([1,3]dioxolo[4,5-g]quinazolin-8-yl)-(3'-methylphenyl)amine hydrochloride 
• 1348218-00-7 ([1,3]dioxolo[4,5-g]quinazolin-8-yl)-(3'-trifluoromethylphenyl)amine hydrochloride 
• 1266869-09-3 ([1,3]dioxolo[4,5-g]quinazolin-8-yl)-(4'-bromo-2'-fluorophenyl)amine hydrochloride 
• 1266868-75-0 ([1,3]dioxolo[4,5-g]quinazolin-8-yl)-(3'-chloro-4'-fluorophenyl)amine hydrochloride 

Relevant academic research and scientific papers

COMPOSITIONS AND METHODS FOR TREATING CANCER

The present disclosure relates to compounds that are capable penetrating to the blood brain barrier to modulate the activity of EGFR tyrosine kinase. The disclosure further relates to methods of treating Glioblastoma and other EGFR mediated cancers. The disclosure further relates to methods of treating Glioblastoma and other EGFR mediated cancers that have been determined to have altered glucose metabolism in the presence of inhibitors. The present disclosure also provides methods of administering to a subject a glucose metabolism inhibitor and a cytoplasmic p53 stabilizer.

COMPOSITIONS AND METHODS FOR TREATING CANCER

The present disclosure relates to compounds that are capable penetrating to the blood brain barrier to modulate the activity of EGFR tyrosine kinase. The disclosure further relates to methods of treating Glioblastoma and other EGFR mediated cancers. The disclosure further relates to methods of treating Glioblastoma and other EGFR mediated cancers that have been determined to have altered glucose metabolism in the presence of inhibitors. The present dislcsoure also provides methods oadministering to a subject a glucose metabolism inhibitor and a cytoplasmic p53 stabilizer.

Quinazoline-based multi-tyrosine kinase inhibitors: Synthesis, modeling, antitumor and antiangiogenic properties

In this work the synthesis and the biological evaluation of some novel anilinoquinazoline derivatives carrying modifications in the quinazoline scaffold and in the aniline moiety were reported. Preliminary cytotoxicity studies identified three derivatives

Design, synthesis, and DNA-binding of N-alkyl(anilino)quinazoline derivatives

New N-alkylanilinoquinazoline derivatives 5, 12, 20, and 22 have been prepared from 4-chloro-6,7-dimethoxyquinazoline 3, 4-chloro-6,7- methylenedioxyquinazoline 19, and commercially available anilines. Differents classes of compounds substituted by an aryloxygroup (6a-c, 16a,b, and 17a,b), (aminophenyl)ureas (12a,b and 13a-f), anilines (4a-m, 20a,b), N-alkyl(aniline) (5a-m, 21a,b, 22a,d), and N-aminoalkyl(aniline) (22e-g) have been synthesized. These molecules were evaluated for their cytotoxic activities and as potential DNA intercalating agents. We studied the strength and mode of binding to DNA of these molecules by DNA melting temperature measurements, fluorescence emission, and circular dichroism. The results of various spectral and gel electrophoresis techniques obtained with the different compounds, in particular compounds 5g and 22f, revealed significant DNA interaction. These experiments confirm that the N-aminoalkyl(anilino)-6,7-dimethoxyquinazoline nucleus is an efficient pharmacophore to trigger binding to DNA, via an intercalative binding process.

Exploring Epidermal Growth Factor Receptor (EGFR) inhibitor features: The role of fused dioxygenated rings on the quinazoline scaffold

A number of dioxolane, dioxane, and dioxepine quinazoline derivatives have been synthetized, and evaluated as EGFR inhibitors. Their cytotoxic activity has been tested against two cell, lines overexpressing and not expressing EGFR. Most derivatives were a

Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases

The present invention relates to compounds of the formula (I) and to pharmaceutically acceptable salts thereof, wherein R1-R4and Z are as defined herein. The compounds of formula (I) are useful as antiproliferative agents. The invent